• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Introduction to 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE (CAS No. 952206-30-3)

6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE, identified by the Chemical Abstracts Service Number (CAS No.) 952206-30-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and chemical research due to its versatile structural framework and potential biological activities. This compound belongs to the imidazopyridine class, a family of molecules known for their broad spectrum of applications in medicinal chemistry. The presence of both bromine and cyano functional groups in its structure enhances its utility as a synthetic intermediate, particularly in the development of novel therapeutic agents.

The structural motif of 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE consists of an imidazo[1,2-a]pyridine core, which is a fused bicyclic system incorporating an imidazole ring and a pyridine ring. This particular arrangement creates a rigid scaffold that can be readily modified through various chemical reactions, making it an attractive scaffold for drug discovery. The bromine atom at the 6-position and the cyano group at the 7-position serve as key handles for further functionalization, allowing chemists to introduce additional substituents or linkages that may enhance binding affinity or bioavailability.

In recent years, there has been a growing interest in imidazopyridine derivatives due to their demonstrated efficacy in various pharmacological contexts. For instance, studies have shown that compounds within this class exhibit properties such as kinase inhibition, anti-inflammatory effects, and antimicrobial activity. The brominated derivative, in particular, has been explored for its potential role in Suzuki-Miyaura cross-coupling reactions, which are widely used in the synthesis of complex organic molecules. The cyano group also provides a site for further transformations, such as reduction to an amine or hydrolysis to a carboxylic acid, expanding the synthetic possibilities.

One of the most compelling aspects of 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE is its utility as a building block in the synthesis of more intricate molecules. Researchers have leveraged this compound to develop novel inhibitors targeting specific disease pathways. For example, recent studies have highlighted its application in generating small-molecule probes that interact with protein kinases involved in cancer progression. The ability to modify both the bromine and cyano positions allows for fine-tuning of physicochemical properties such as solubility and metabolic stability, which are critical factors in drug development.

The pharmaceutical industry has been particularly keen on exploring heterocyclic compounds like 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE due to their historical success in drug discovery. Many FDA-approved drugs contain imidazopyridine moieties as part of their structure, underscoring their importance in medicinal chemistry. The bromine substituent at the 6-position is particularly valuable because it can be easily displaced by nucleophiles under mild conditions, facilitating the introduction of diverse functional groups. This feature has been exploited in numerous synthetic strategies aimed at generating libraries of compounds for high-throughput screening.

Moreover, the cyano group at the 7-position adds another layer of reactivity to 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE. It can be converted into other functional groups through standard organic transformations, such as hydrolysis to form a carboxylic acid or reduction to yield an amine. These transformations are essential for tailoring the compound’s properties to meet specific biological requirements. For instance, converting the cyano group into an amine might improve solubility or enhance binding interactions with biological targets.

Recent advances in computational chemistry have also contributed to the growing interest in 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE. Molecular modeling studies have revealed that this compound can interact with various biological targets through multiple hydrogen bonds and hydrophobic interactions. These insights have guided researchers in designing derivatives with enhanced binding affinities or selectivities. Additionally, virtual screening techniques have been employed to identify potential lead compounds based on their structural similarity to known active molecules.

The synthesis of 6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE typically involves multi-step organic reactions starting from commercially available precursors. One common approach involves the condensation of 2-aminothiazole with 3-bromopyridine-2-carbaldehyde under basic conditions followed by cyclization and subsequent introduction of the cyano group. This synthetic route highlights the compound’s accessibility and underscores its suitability for large-scale production if needed.

In conclusion,6-BROMOIMIDAZO[1,2-A]PYRIDINE-7-CARBONITRILE (CAS No. 952206-30-3) represents a valuable scaffold for pharmaceutical research due to its structural versatility and reactivity. Its applications span from serving as a synthetic intermediate to being a precursor for biologically active molecules targeting various diseases. The ongoing exploration of this compound underscores its significance in modern drug discovery efforts and highlights its potential as a key component in future therapeutic developments.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)